Vernakalant: Medikamentöse Kardioversion bei Vorhofflimmern

Pharmacological Cardioversion of Atrial Fibrillation. Background: Intravenous Vernakalant has been approved in Austria in January 2011 as an atrial-selective antiarrhythmic drug for the acute conversion of recent-onset atrial fibrillation (≤ 7 days). Due to its atrial-selective properties, vernakalant prolongs the effective refractory period of the atria with minimal effects on the ventricles, being associated with a low proarrhythmic risk. Vernakalant is dosed by patient body weight to be infused over a 10 minutes period in a monitored clinical setting. Methods: A total of 48 patients (pts.) (22